Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Corp.

The latest update is out from Profound Medical ( ($TSE:PRN) ). Profound Medical Corp., a commercial-stage medical device maker of AI-powered, MRI-g...

Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures

Profound Medical ( ($TSE:PRN) ) has issued an update. On March 13, 2026, Profound Medical announced that its multicenter CAPTAIN randomized control...

Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes

The latest announcement is out from Profound Medical ( ($TSE:PRN) ). On March 5, 2026, Profound Medical Corp. announced that director Kris Shah res...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PROF	$6.48	+1.57%	30.54K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PROF	$6.48	+1.6%	30.54K
3
4
5
6

PROF

PROF

Dividend Overview

Get Profound Medical Corp. Data in Excel

Get Profound Medical Corp. Data in Excel